outcomes and treatment strategies of metastatic ILC. This retrospective study evaluates the overall survival (OS) and progression-free survival (PFS) in the metastatic ILC population at a single institution, focusing on first line treatment received in the
Search Results
CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience
Hinda Boutrid, Maryam Lustberg, Jeffrey Vandeusen, Sagar Sardesai, Daniel Stover, Robert Wesolowski, Mathew Cherian, Julie Stephens, Marilly Palettas, Evan Morgan, Mohmoud Kassem, Michael Berger, Craig A. Vargo, Bhuvaneswari Ramaswamy, and Nicole Williams
HSR19-107: Nivolumab for Newly Diagnosed Classical Hodgkin Lymphoma: Patient-Reported Outcomes From CheckMate 205 Cohort D
Radhakrishnan Ramchandren, Stephen M. Ansell, Philippe Armand, Andreas Engert, Fiona Taylor, Kim Cocks, Clara Chen, Bryan Bennett, Alejandro Moreno-Koehler, Adam Roeder, Anne Sumbul, Mariana Sacchi, and David Cella
checkpoint inhibitor monoclonal antibody, demonstrated efficacy and clinically meaningful improvement in pt-reported outcomes (PROs) in pts with relapsed/refractory cHL in cohorts A, B, and C of CheckMate 205 (NCT02181738) (Armand et al, J Clin Oncol 2018
QIM19-129: Utilization of Electronic Medical Record to Improve Outcomes in the Treatment of Febrile Neutropenia
Anna M. Gibson and Claire Sutherby
Introduction: Chemotherapy-induced febrile neutropenia is a medical emergency. Delays in time to appropriate broad spectrum antibiotic therapy significantly increase morbidity and mortality. The purpose of this project is to improve outcomes in
Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Ali A. Mokdad, Amit G. Singal, Jorge A. Marrero, Hao Zhu, and Adam C. Yopp
for HCC remains below 20% in the United States. 2 Poor HCC outcomes are largely attributed to low rates of HCC surveillance and high rates of late stage diagnosis. 3 , 4 Accurate HCC staging is important for patient prognostication, treatment
Issues of Imatinib and Pregnancy Outcome
Jane Apperley
to have functions that may be important in gonadal development, implantation, and fetal development. 1 - 5 An international registry of pregnancy outcome was recently established by Novartis to compile pregnancy outcomes in women who have been
Predictors of Outcome in Bladder Cancer
John B. Eifler, Daniel A. Barocas, and Matthew J. Resnick
) remains low, and selecting the subset of patients most likely to benefit from NAC has proven difficult. Patients with organ-confined MIBC have experienced excellent oncologic outcomes absent the use of NAC (5-year disease-specific survival of ≈80%). 12
Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level
Vinayak Muralidhar, Paul L. Nguyen, Brandon A. Mahal, David D. Yang, Kent W. Mouw, Brent S. Rose, Clair J. Beard, Jason A. Efstathiou, Neil E. Martin, Martin T. King, and Peter F. Orio III
focused on receipt of locoregional treatment, compared with others with N0M0 disease, node-positive disease, or metastatic disease. We also studied survival outcomes among these various subgroups of patients and explored the possible survival benefit
SupportScreen: A Model for Improving Patient Outcomes
Matthew Loscalzo, Karen Clark, Jeff Dillehunt, Redmond Rinehart, Rex Strowbridge, and Daniel Smith
authors have taken this process a step further by automating biopsychosocial screening through the use of touch-screen technology. 12 SupportScreen Improved Patient Outcomes “At Your Fingertips” The authors' team developed a new touch screen
Patient-Reported Outcomes in Multiple Myeloma
Stephanie J. Lee
multiple myeloma . N Engl J Med 2003 ; 348 : 1875 – 1883 . 6 American Society of Clinical Oncology . Outcomes of cancer treatment for technology assessment and cancer treatment guidelines . J Clin Oncol 1996 ; 14 : 671 – 679 . 7
A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma
David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner, and Henry S. Friedman
associated with poor outcome among patients with glioblastoma. 30 , 31 VEGF-A isoforms generated by alternative splicing can also originate from host sources, such as invading macrophages and platelets, whereas tumor stroma can sequester larger isoforms that
